• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down 1.83% Nasdaq Down 1.20%

    Keryx Biopharmaceuticals Inc. (KERX)

    -NasdaqCM
    4.79 Down 0.27(5.33%) 12:42PM EDT - Nasdaq Real Time Price
    Add to Portfolio
    Prev Close:5.06
    Open:4.98
    Bid:4.75 x 400
    Ask:4.76 x 300
    1y Target Est:14.22
    Beta:6.19889
    Earnings Date:Nov 4 - Nov 9 (Est.)
    Day's Range:4.59 - 4.99
    52wk Range:4.59 - 18.01
    Volume:2,588,758
    Avg Vol (3m):1,613,850
    Market Cap:503.78M
    P/E (ttm):N/A
    EPS (ttm):-1.34
    Div & Yield:N/A (N/A)
    Quotes delayed, except where indicated otherwise. Currency in USD.

    Comparison

    Symbol% ChgMkt Cap
    KERXDown 5.33%503.78M
    BAXDown 2.67%19.67B

    Key Statistics

    Forward P/E (1 yr):N/A
    P/S (ttm):117.89
    Ex-Dividend Date:N/A

    Analysts

    Annual EPS Est (Dec-15) :-1.02
    Quarterly EPS Est (Sep-15) :-0.25
    Mean Recommendation*:2.5
    PEG Ratio (5 yr expected):-0.05

    * (Strong Buy) 1.0 - 5.0 (Sell)

    Analyst Opinion | Estimates

    Business Summary

    Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity ... View More
    Your browser doesn't support canvas
    SETTINGS
    Scrolling
    Speed
    Display
    Price
    Submit Feedback